iRhythm Technologies (IRTC) Financials

iRhythm Technologies’ latest quarter shows a company with solid liquidity, improving revenue, but still inconsistent profitability and meaningful leverage. In Q1 2026, revenue rose to $199.4 million, up from $186.7 million in Q2 2025 and $158.7 million in Q1 2025. However, the company posted a net loss of $13.9 million in the quarter, after a $5.6 million profit in Q4 2025. Cash generation also weakened, with operating cash flow turning negative again in Q1 2026.

Over the last several years, the biggest trend is growth paired with recurring earnings volatility. Revenue has generally moved higher from the low $100 million range in early 2023 to nearly $200 million in the latest quarter. But operating margins have remained under pressure because selling, general and administrative expenses continue to run very high relative to gross profit, and quarterly results have swung between losses and brief profits.

Balance sheet strength remains an important offset. As of Q1 2026, iRhythm held $240.1 million in cash and equivalents plus $309.5 million in short-term investments, along with $72.9 million in long-term investments. That gives the company a sizable liquidity cushion. Still, long-term debt of $650.3 million is much larger than equity of $161.2 million, so leverage is a clear factor investors need to watch.

• Revenue continues to trend upward year over year, suggesting the core business is still expanding.
• Gross profit remains strong, with Q1 2026 gross margin around 71%, indicating the product itself is still highly profitable before operating expenses.
• The company ended Q1 2026 with more than $550 million in cash and short-term investments combined, providing near-term financial flexibility.
• Interest and investment income helps offset losses, adding $4.9 million in Q1 2026.
• Revenue growth has been steady from 2023 through 2026, pointing to continued demand momentum.
• Capital spending appears manageable, with Q1 2026 PP&E purchases of $6.9 million.
• Share count has been relatively stable, so dilution has not been the main issue recently.
• Long-term investments and a large cash position reduce immediate balance sheet risk, even with leverage.
• Q1 2026 operating loss of $16.2 million shows the company is still not consistently profitable at the operating level.
• Operating cash flow was negative $26.2 million in Q1 2026, a deterioration from positive operating cash flow in Q4 2025.

Expense growth is the main reason profitability remains elusive. In Q1 2026, SG&A was $135.9 million versus gross profit of $141.4 million, leaving very little room for operating profit after R&D and other costs. That same pattern appears throughout the prior years: revenue has grown, but operating expenses have often grown almost as fast.

The cash flow picture is mixed. iRhythm has often generated operating cash flow even when net income was negative, thanks to large non-cash charges such as depreciation, amortization, and other adjustments. But the quarterly swings are significant. Q1 2026 saw negative operating cash flow, while Q4 2025 and several earlier quarters were positive. That inconsistency makes the business look less predictable.

From a risk perspective, debt is the biggest concern. Long-term debt has stayed above $640 million for most of the period shown, while shareholders’ equity has been much smaller and even declined sharply in some periods. Although liquidity is currently healthy, the company’s capital structure could become a problem if growth slows or losses persist.

Bottom line: iRhythm Technologies looks like a growth company with a strong cash position and improving revenue, but investors should not ignore the persistent operating losses, negative free cash flow in the latest quarter, and sizable debt load. The stock’s long-term case likely depends on whether management can translate revenue growth into durable operating leverage.